BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 25, 2007
View Archived Issues
Adnexus Nixes IPO Route, Opts For $430M BMS Exit
Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)
Read More
Celgene Paying Array $40M Up Front For Drug Discovery
Read More
Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus
Read More
Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug
Read More
Elixir Aiming For Public Markets With $86M IPO
Read More
Other News To Note
Read More
Clinic Roundup
Read More